Hong Kong-based conglomerate Jardine Matheson is making a major move into healthcare diagnostics, announcing on Monday that it has agreed to acquire Australian medical imaging provider I-MED Radiology Network in a deal valued at A$3.4 billion (approximately $2.4 billion).
The acquisition marks one of Jardines’ biggest healthcare investments to date and signals the company’s growing interest in sectors tied to long-term demographic and technological growth.
A Strategic Expansion Beyond Retail and Property
Known historically for its investments across property, automotive, retail, hospitality, and financial services, Jardine Matheson said it will acquire a 100 percent stake in I-MED from funds advised by private equity giant Permira and other shareholders.
The transaction will be funded through a combination of existing cash reserves and debt financing, although the company did not disclose the exact breakdown.
The deal also includes I-MED’s minority stake in Harrison.ai, an Australian firm developing artificial intelligence solutions for radiology and medical diagnostics.
For Jardines, the acquisition reflects a broader strategic shift toward businesses positioned around healthcare demand, ageing populations, and AI-driven innovation.
In a statement, the company said the purchase aligns with its strategy of investing in “market-leading businesses” while expanding into high-growth sectors.
Why I-MED Matters
I-MED is currently one of the largest diagnostic imaging providers in Australia and New Zealand, operating 215 clinics across the region and conducting more than seven million procedures annually.
The company offers a wide range of imaging services including MRI, CT scans, ultrasounds, mammography, and nuclear medicine. It also operates teleradiology services, enabling radiologists to remotely interpret medical scans across Australia, New Zealand, and the United States.
Healthcare diagnostics has become an increasingly attractive investment area globally as healthcare systems expand their reliance on early detection, imaging technology, and AI-assisted diagnostics.
The inclusion of the Harrison.ai stake gives the acquisition an additional technology angle, particularly as hospitals and imaging providers increasingly explore machine learning tools to improve speed and accuracy in medical analysis.
Valuation and Financial Outlook
Jardine Matheson said the transaction values I-MED at approximately 11.5 times forecast adjusted EBITDA for the financial year ending June 2026, excluding the value of the Harrison.ai investment.
EBITDA — earnings before interest, taxes, depreciation, and amortisation — is commonly used by investors to evaluate operational profitability.
The conglomerate added that the acquisition is expected to be neutral to underlying earnings per share during its first full year after completion before becoming accretive in subsequent years.
Jardines CEO Lincoln Pan, who assumed the role in December, described I-MED as a long-term growth opportunity.
“I-MED is already a market leader in radiology today, and we expect the business will expand further in I-MED’s core markets as well as new markets,” Pan said in the company statement.
A Broader Transformation at Jardines
The I-MED acquisition comes during a period of strategic restructuring for Jardine Matheson as the 192-year-old conglomerate repositions itself for future growth areas beyond its traditional businesses.
In January, the company completed the buyout of luxury hotel group Mandarin Oriental Hotel Group, further consolidating control over one of its flagship hospitality brands.
The latest healthcare acquisition suggests Jardines is increasingly seeking stable, long-term revenue streams linked to essential services rather than purely cyclical consumer sectors.
The I-MED transaction remains subject to regulatory approvals and is expected to close later in 2026.
